NASDAQ:NKTR - Nektar Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$48.36 +0.57 (+1.19 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$47.79
Today's Range$47.10 - $49.08
52-Week Range$17.51 - $111.36
Volume1.30 million shs
Average Volume3.67 million shs
Market Capitalization$8.19 billion
P/E Ratio-87.93
Dividend YieldN/A
Beta1.96
Nektar Therapeutics logoNektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300

Debt

Debt-to-Equity Ratio4.21
Current Ratio4.16
Quick Ratio4.03

Price-To-Earnings

Trailing P/E Ratio-87.93
Forward P/E Ratio14.31
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.71 million
Price / Sales269.91
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book86.36

Profitability

EPS (Most Recent Fiscal Year)($0.55)
Net Income$-96,690,000.00
Net Margins-40.07%
Return on Equity-202.41%
Return on Assets-22.92%

Miscellaneous

Employees509
Outstanding Shares171,400,000
Market Cap$8,191.30

The Truth About Cryptocurrencies

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.08. The biopharmaceutical company earned $38.02 million during the quarter, compared to analyst estimates of $35.59 million. Nektar Therapeutics had a negative net margin of 40.07% and a negative return on equity of 202.41%. The company's revenue for the quarter was up 53.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.42) earnings per share. View Nektar Therapeutics' Earnings History.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Nektar Therapeutics.

What price target have analysts set for NKTR?

12 brokerages have issued twelve-month target prices for Nektar Therapeutics' stock. Their forecasts range from $20.00 to $125.00. On average, they anticipate Nektar Therapeutics' stock price to reach $81.1818 in the next year. This suggests a possible upside of 67.9% from the stock's current price. View Analyst Ratings for Nektar Therapeutics.

What is the consensus analysts' recommendation for Nektar Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nektar has a promising pipeline with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent co-development deal with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 is encouraging. The deals provide revenues as well as reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company. Shares of the company have outperformed the industry in the past one year. Estimates have remained stable ahead of the company’s Q2 earnings release. Nektar has a mixed record of earnings surprises in recent quarters." (7/16/2018)
  • 2. Mizuho analysts commented, "We believe Keytruda’s data reinforces our thesis on Nektar. Assuming positive data at ASCO, we believe BMS would be inclined to make a bid for Nektar given its deteriorating market position relative to Merck." (4/17/2018)

Are investors shorting Nektar Therapeutics?

Nektar Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 16,926,100 shares, an increase of 33.4% from the May 31st total of 12,686,538 shares. Based on an average daily volume of 9,900,153 shares, the days-to-cover ratio is presently 1.7 days. Currently, 10.0% of the shares of the stock are short sold. View Nektar Therapeutics' Current Options Chain.

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 65)
  • Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 46)
  • Mr. John Nicholson, Sr. VP & COO (Age 66)
  • Dr. Stephen K. Doberstein, Sr. VP of R&D and Chief R&D Officer (Age 59)
  • Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 64)

Has Nektar Therapeutics been receiving favorable news coverage?

Media stories about NKTR stock have trended somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nektar Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.27%), Retirement Systems of Alabama (0.08%), Bank of Montreal Can (0.08%), Franklin Street Advisors Inc. NC (0.03%), Gulf International Bank UK Ltd (0.03%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

Which institutional investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Rathbone Brothers plc and Fortaleza Asset Management Inc.. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Which institutional investors are buying Nektar Therapeutics stock?

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Scout Investments Inc., Retirement Systems of Alabama, Franklin Street Advisors Inc. NC, Gulf International Bank UK Ltd, Fjarde AP Fonden Fourth Swedish National Pension Fund, State of Alaska Department of Revenue and DnB Asset Management AS. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $48.36.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $8.19 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  435 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  646
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.